News
AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat ...
The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a ...
8h
Zacks Investment Research on MSNFDA Grants Label Expansion to AstraZeneca's Datroway in Lung CancerAstraZeneca AZN announced that the FDA has expanded the label of its cancer drug Datroway for a second indication — non-small ...
FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response ...
Approval was based on results from the Phase II TROPION-Lung05 trial, which showed that Datroway demonstrated a strong ...
12h
GlobalData on MSNFDA approves AstraZeneca and Daiichi Sankyo’s Datroway for NSCLCThe US Food and Drug Administration (FDA) has approved AstraZeneca and Daiichi Sankyo's Datroway (Datopotamab deruxtecan) for ...
AstraZeneca (NASDAQ:AZN) on Monday night received accelerated approval from the U.S. Food and Drug Administration (FDA) for its lung cancer drug Datroway.
Drugmaker AstraZeneca's Datroway has been approved in the US for adult patients with previously treated advanced EGFR-mutated ...
AstraZeneca (NASDAQ:AZN) on Monday night received accelerated approval from the U.S. Food and Drug Administration (FDA) for its lung cancer drug Datroway. The approval covers use in patients with EGFR ...
Fourteen years after AstraZeneca’s blood thinner Brilinta reached the market and now faces generic competition, the data that ...
Fresh concerns have emerged about the platelet studies underpinning the FDA approval of ticagrelor, AstraZeneca's ...
AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results